Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 510,812 shares, an increase of 316.9% from the February 12th total of 122,516 shares. Currently, 32.3% of the shares of the stock are sold short. Based on an average daily volume of 21,928,279 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 21,928,279 shares, the short-interest ratio is presently 0.0 days. Currently, 32.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cardio Diagnostics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Cardio Diagnostics Trading Down 4.2%

NASDAQ CDIO opened at $4.56 on Friday. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $17.39. The stock has a 50-day simple moving average of $2.68 and a 200 day simple moving average of $3.34. The company has a market capitalization of $8.34 million, a PE ratio of -1.22 and a beta of 2.28.

Institutional Trading of Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC bought a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.